Recent advances in the development of MMPIs and APNIs based on the pyrrolidine platforms

Mini-Reviews in Medicinal Chemistry

Volumn 10, Issue 9, 2010, Pages 794-805

  Li, X ^a   Li, J ^b  

^a SHANDONG UNIVERSITY   (China)

^b LIAOCHENG PEOPLE'S HOSPITAL   (China)

Author keywords

Anticancer; APNIs; Design; MMPIs; Pyrrolidine

Indexed keywords

ANTINEOPLASTIC AGENT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MICROSOMAL AMINOPEPTIDASE; PROTEINASE INHIBITOR; PYRROLIDINE DERIVATIVE;

ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG DESIGN; METABOLISM;

ANTIGENS, CD13; ANTINEOPLASTIC AGENTS; DRUG DESIGN; MATRIX METALLOPROTEINASE INHIBITORS; MATRIX METALLOPROTEINASES; PROTEASE INHIBITORS; PYRROLIDINES;

EID: 77956576575     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/138955710791608334     Document Type: Article

References (87)

1. MacFadyen, R.J. Can matrix metalloproteinase inhibitors provide a realistic therapy in cardiovascular medicine? Curr. Opin. Pharmacol., 2007, 7, 171-178.
2. Murphy, G.; Nagase, H. Progress in matrix metalloproteinase research. Mol. Aspects Med., 2008, 29, 290-308.
3. Stamenkovic, I. Matrix metalloproteinases in tumor invasion and metastasis. Semin. Cancer Biol., 2000, 10, 415-433.
4. Ramnath, N.; Creaven, P.J. Matrix metalloproteinase inhibitors. Curr. Oncol. Rep., 2004, 6, 96-102.
5. Pietruska, M.; Pietruski, J.; Skurska, A.; Bernaczyk, A.; Zak, J.; Zelazowska, B.; Doli, E.; Paniczko-Drezek, A.; Wysocka, J. Assessment of aprotinin influence on periodontal clinical status and matrix metalloproteinases 1, 2 and their tissue inhibitors saliva concentrations in patients with chronic periodontitis. Adv. Med. Sci., 2009, 54, 239-246.
6. Gharagozlian, S.; Svennevig, K.; Bangstad, H.J.; Winberg, J.O.; Kolset, S.O. Matrix metalloproteinases in subjects with type 1 diabetes. BMC. Clin. Pathol., 2009, 9, 7.
7. Matsumoto, Y.; Park, I.K.; Kohyama, K. Matrix metalloproteinase (MMP)-9, but not MMP-2, is involved in the development and progression of C protein-induced myocarditis and subsequent dilated cardiomyopathy. J. Immunol., 2009, 183, 4773-4781.
8. Hu, J.; Van den Steen, P.E.; Sang, Q.X.; Opdenakker, G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat. Rev. Drug Discov., 2007, 6, 480-498.
9. Sang, Q.X.; Jin, Y.; Newcomer, R.G.; Monroe, S.C.; Fang, X.; Hurst, D.R.; Lee, S.; Cao, Q.; Schwartz, M.A. Matrix metalloproteinase inhibitors as prospective agents for the prevention and treatment of cardiovascular and neoplastic diseases. Curr. Top Med. Chem., 2006, 6, 289-316.
10. Shah, V.K.; Shalia, K.K.; Mashru, M.R.; Soneji, S.L.; Abraham, A.; Kudalkar, K.V.; Vasvani, J.B.; Sanghavi, S.T. Role of matrix metalloproteinases in coronary artery disease. Indian Heart J., 2009, 61, 44-50.
11. Zou, Y.; Chen, Y.; Jiang, Y.; Gao, J.; Gu, J. Targeting matrix metalloproteinases and endothelial cells with a fusion peptide against tumor. Cancer Res., 2007, 67, 7295-7300.
12. Whittaker, M.; Floyd, C.D.; Brown, P.; Gearing, A.J. Design and therapeutic application of matrix metalloproteinase inhibitors. Chem. Rev., 1999, 99, 2735-2776.
13. Nuti, E.; Tuccinardi, T.; Rossello, A. Matrix metalloproteinase inhibitors: New challenges in the era of post broad-spectrum inhibitors. Curr. Pharm. Des., 2007, 13, 2087-2100.
14. Kleiner, D.E.; Stetler-Stevenson, W.G. Matrix metalloproteinases and metastasis. Cancer Chemother. Pharmacol., 1999, 43 Suppl, S42-S51.
15. Overall, C.M.; Kleifeld, O. Tumour microenvironment-opinion: Validating matrix metalloproteinases as drug targets and antitargets for cancer therapy. Nat. Rev. Cancer., 2006, 6, 227-239.
16. Brown, P.D. Matrix metalloproteinase inhibitors. Breast Cancer Res. Treat., 1998, 52, 125-136.
17. Konstantinopoulos, P.A.; Karamouzis, M.V.; Papatsoris, A.G.; Papavassiliou, A.G. Matrix metalloproteinase inhibitors as anticancer agents. Int. J. Biochem. Cell Biol., 2008, 40, 1156-1168.
18. Vihinen, P.; Ala-aho, R.; Kahari, V.M. Matrix metalloproteinases as therapeutic targets in cancer. Curr. Cancer Drug Targets, 2005, 5, 203-220.
19. Fisher, J.F.; Mobashery, S. Recent advances in MMP inhibitor design. Cancer Metastasis. Rev., 2006, 25, 115-136.
20. Renkiewicz, R.; Qiu, L.; Lesch, C.; Sun, X.; Devalaraja, R.; Cody, T.; Kaldjian. E. Welgus, H. Baragi, V. Broad-spectrum matrix metalloproteinase inhibitor Marimastat-induced musculoskeletal side effects in rats. Arthritis. Rheum., 2003, 48, 1742-1749.
21. Mannello, F.; Tonti, G.; Papa, S. Matrix metalloproteinase inhibitors as anticancer therapeutics. Curr. Cancer Drug Targets, 2005, 5, 285-298.
22. Coussens, L.M.; Fingleton, B.; Matrisian, L.M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science, 2002, 295, 2387-2392.
23. Skiles, J.W.; Gonnella, N.C.; Jeng, A.Y. The design, structure, and therapeutic application of matrix metalloproteinase inhibitors. Curr. Med. Chem., 2001, 8, 425-474.
24. Skiles, J.W.; Gonnella, N.C.; Jeng, A.Y. The design, structure, and clinical update of small molecular weight matrix metalloproteinase inhibitors. Curr. Med. Chem., 2004, 11, 2911-2977.
25. Rowsell, S.; Hawtin, P.; Minshull, C.A.; Jepson, H.; Brockbank, S.M.; Barratt, D.G.; Slater, A.M.; McPheat, W.L.; Waterson, D.; Henney, A.M.; Pauptit, R.A. Crystal structure of human MMP9 in complex with a reverse hydroxamate inhibitor. J. Mol. Biol., 2002, 319, 173-181.
26. Dunten, P.; Kammlott, U.; Crowther, R.; Levin, W.; Foley, L.H.; Wang, P.; Palermo, R. X-ray structure of a novel matrix metalloproteinase inhibitor complexed to stromelysin. Protein Sci., 2001, 10, 923-926.
27. Terp, G.E.; Cruciani, G.; Christensen, I.T.; Jørgensen, F.S. Structural differences of matrix metalloproteinases with potential implications for inhibitor selectivity examined by the GRID/CPCA approach. J. Med. Chem., 2002, 45, 2675-2684.
28. Jacobsen, J.A.; Major Jourden, J.L.; Miller, M.T.; Cohen, S.M. To bind zinc or not to bind zinc: An examination of innovative approaches to improved metalloproteinase inhibition. Biochim. Biophys. Acta, 2010, 1803(1), 72-94.
29. Georgiadis, D.; Yiotakis, A. Specific targeting of metzincin family members with small-molecule inhibitors: Progress toward a multifarious challenge. Bioorg. Med. Chem., 2008, 16, 8781-8794.
30. Riemann, D.; Kehlen, A.; Langner, J. CD13--not just a marker in leukemia typing. Immunol. Today, 1999, 20, 83-88.
31. Kehlen, A.; Lendeckel, U.; Dralle, H.; Langner, J.; Hoang-Vu, C. Biological significance of aminopeptidase N/CD13 in thyroid carcinomas. Cancer Res., 2003, 63, 8500-8506.
32. Reinhold, D.; Bank, U.; Täger, M.; Ansorge, S.; Wrenger, S.; Thielitz, A.; Lendeckel, U.; Faust, J.; Neubert, K.; Brocke, S. DP IV/CD26, APN/CD13 and related enzymes as regulators of T cell immunity: implications for experimental encephalomyelitis and multiple sclerosis. Front. Biosci., 2008, 13, 2356-2363.
33. Wulfaenger, J.; Niedling, S.; Riemann, D.; Seliger, B. Aminopeptidase N (APN)/CD13-dependent CXCR4 downregulation is associated with diminished cell migration, proliferation and invasion. Mol. Membr. Biol., 2008, 25, 72-82.
34. Fujii, H.; Nakajima, M.; Saiki, I.; Yoneda, J.; Azuma, I.; Tsuruo, T. Human melanoma invasion and metastasis enhancement by high expression of aminopeptidase N/CD13. Clin. Exp. Metastasis, 1995, 13, 337-344.
35. Ishii, K.; Usui, S.; Sugimura, Y.; Yoshida, S.; Hioki, T.; Tatematsu, M.; Yamamoto, H.; Hirano, K. Aminopeptidase N regulated by zinc in human prostate participates in tumor cell invasion. Int. J. Cancer, 2001, 92, 49-54.
36. Tomanek, R.J.; Schatteman, G.C. Angiogenesis: new insights and therapeutic potential. Anat. Rec., 2000, 261, 126-135.
37. Fukasawa, K.; Fujii, H.; Saitoh, Y.; Koizumi, K.; Aozuka, Y.; Sekine, K.; Yamada, M.; Saiki, I.; Nishikawa, K. Aminopeptidase N (APN/CD13) is selectively expressed in vascular endothelial cells and plays multiple roles in angiogenesis. Cancer Lett., 2006, 243, 135-143.
38. Bhagwat, S.V.; Lahdenranta, J.; Giordano, R.; Arap, W.; Pasqualini, R.; Shapiro, L.H. CD13/APN is activated by angiogenic signals and is essential for capillary tube formation. Blood, 2001, 97, 652-659.
39. Hashida, H.; Takabayashi, A.; Kanai, M.; Adachi, M.; Kondo, K.; Kohno, N.; Yamaoka, Y.; Miyake, M. Aminopeptidase N is involved in cell motility and angiogenesis: its clinical significance in human colon cancer. Gastroenterology, 2002, 122, 376-386.
40. Mina-Osorio, P. The moonlighting enzyme CD13: old and new functions to target. Trends Mol. Med., 2008, 14, 361-371.
41. Ito, K.; Nakajima, Y.; Onohara, Y.; Takeo, M.; Nakashima, K.; Matsubara, F.; Ito, T.; Yoshimoto, T. Crystal structure of aminopeptidase N (proteobacteria alanyl aminopeptidase) from Escherichia coli and conformational change of methionine 260 involved in substrate recognition. J. Biol. Chem., 2006, 281, 33664-33676.
42. Onohara, Y.; Nakajima, Y.; Ito, K.; Xu, Y.; Nakashima, K.; Ito, T.; Yoshimoto, T. Crystallization and preliminary X-ray characterization of aminopeptidase N from Escherichia coli. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun., 2006, 62, 699-701.
43. Addlagatta, A.; Gay, L.; Matthews, B.W. Structural basis for the unusual specificity of Escherichia coli aminopeptidase N. Biochemistry, 2008, 47, 5303-5311.
44. Addlagatta, A.; Gay, L.; Matthews, B.W. Structure of aminopeptidase N from Escherichia coli suggests a compartmentalized, gated active site. Proc. Natl. Acad. Sci. U S A., 2006, 103, 13339-13344.
45. O'Brien, P.M.; Ortwine, D.F.; Pavlovsky, A.G.; Picard, J.A.; Sliskovic, D.R.; Roth, B.D.; Dyer, R.D.; Johnson, L.L.; Man, C.F.; Hallak, H. Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors. J. Med. Chem., 2000, 43, 156-166.
46. Oltenfreiter, R.; Staelens, L.; Lejeune, A.; Dumont, F.; Frankenne, F.; Foidart, J.M.; Slegers, G. New radioiodinated carboxylic and hydroxamic matrix metalloproteinase inhibitor tracers as potential tumor imaging agents. Nucl. Med. Biol., 2004, 31, 459-468.
47. Cheng, M.; De, B.; Almstead, N.G.; Pikul, S.; Dowty, M.E.; Dietsch, C.R.; Dunaway, C.M.; Gu, F.; Hsieh, L.C.; Janusz, M.J.; Taiwo, Y.O.; Natchus, M.G.; Hudlicky, T.; Mandel, M. Design, synthesis, and biological evaluation of matrix metalloproteinase inhibitors derived from a modified proline scaffold. J. Med. Chem., 1999, 42, 5426-5436.
48. Tsai, K.C.; Lin, T.H. A ligand-based molecular modeling study on some matrix metalloproteinase-1 inhibitors using several 3D QSAR techniques. J. Chem. Inf. Comput. Sci., 2004, 44, 1857-1871.
49. Natchus, M.G.; Bookland, R.G.; De, B.; Almstead, N.G.; Pikul, S.; Janusz, M.J.; Heitmeyer, S.A.; Hookfin, E.B.; Hsieh, L.C.; Dowty, M.E.; Dietsch, C.R.; Patel, V.S.; Garver, S.M.; Gu, F.; Pokross, M.E.; Mieling, G.E.; Baker, T.R.; Foltz, D.J.; Peng, S.X.; Bornes, D.M.; Strojnowski, M.J.; Taiwo, Y.O. Development of new hydroxamate matrix metalloproteinase inhibitors derived from functionalized 4-aminoprolines. J. Med. Chem., 2000, 43, 4948-4963.
50. Gupta, S.P.; Kumar, D.; Kumaran, S. A quantitative structureactivity relationship study of hydroxamate matrix metalloproteinase inhibitors derived from functionalized 4-aminoprolines. Bioorg. Med. Chem., 2003, 11, 1975-1981.
51. Janusz, M.J.; Hookfin, E.B.; Brown, K.K.; Hsieh, L.C.; Heitmeyer, S.A.; Taiwo, Y.O.; Natchus, M.G.; Pikul, S.; Almstead, N.G.; De, B.; Peng, S.X.; Baker, T.R.; Patel, V. Comparison of the pharmacology of hydroxamate and carboxylate-based matrix metalloproteinase inhibitors (MMPIs) for the treatment of osteoarthritis. Inflamm. Res., 2006, 55, 60-65.
52. Santos, M.A.; Marques, S.; Gil, M.; Tegoni, M.; Scozzafava, A.; Supuran, C.T. Protease inhibitors: synthesis of bacterial collagenase and matrix metalloproteinase inhibitors incorporating succinyl hydroxamate and iminodiacetic acid hydroxamate moieties J. Enzyme Inhib. Med. Chem., 2003, 18, 233-242.
53. 2+. J. Inorg. Biochem., 2004, 98, 209-218.
54. Skiles, J.W.; Gonnella, N.C.; Jeng, A.Y. The design, structure, and therapeutic application of matrix metalloproteinase inhibitors. Curr. Med. Chem., 2001, 8, 425-474.
55. Overall, C.M.; Kleifeld, O. Towards third generation matrix metalloproteinase inhibitors for cancer therapy. Br. J. Cancer, 2006, 94, 941-946.
56. Lovejoy, B.; Welch, A.R.; Carr, S.; Luong, C.; Broka, C.; Hendricks, R.T.; Campbell, J.A.; Walker, K.A. Martin, R.; Van Wart, H.; Browner, M.F. Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors. Nat. Struct. Biol., 1999, 6(3), 217-221.
57. Verma, R.P.; Hansch, C. Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs. Bioorg. Med. Chem., 2007, 15, 2223-2268.
58. Pochetti, G.; Montanari, R.; Gege, C.; Chevrier, C.; Taveras, A.G.; Mazza, F. Extra binding region induced by non-zinc chelating inhibitors into the S1' subsite of matrix metalloproteinase 8 (MMP8). J. Med. Chem., 2009, 52, 1040-1049.
59. Yiotakis, A.; Dive, V. Synthetic active site-directed inhibitors of metzincins: achievement and perspectives. Mol. Aspects Med., 2008, 29, 329-338.
60. Rosenblum, G.; Meroueh, S.O.; Kleifeld, O.; Brown, S.; Singson, S.P.; Fridman, R.; Mobashery, S.; Sagi, I. Structural basis for potent slow binding inhibition of human matrix metalloproteinase-2 (MMP-2). J. Biol. Chem., 2003, 278, 27009-27015.
61. Devel, L.; Rogakos, V.; David, A.; Makaritis, A.; Beau, F.; Cuniasse, P.; Yiotakis, A.; Dive, V. Development of selective inhibitors and substrate of matrix metalloproteinase-12. J. Biol. Chem., 2006, 281, 11152-11160.
62. Engel, C.K.; Pirard, B.; Schimanski, S.; Kirsch, R.; Habermann, J.; Klingler, O.; Schlotte, V.; Weithmann, K.U.; Wendt, K.U. Structural basis for the highly selective inhibition of MMP-13. Chem. Biol., 2005, 12, 181-189.
63. Hanessian, S.; MacKay, D.B.; Moitessier, N. Design and synthesis of matrix metalloproteinase inhibitors guided by molecular modeling. Picking the S(1) pocket using conformationally constrained inhibitors. J. Med. Chem., 2001, 44, 3074-3082.
64. Fernández, M.; Caballero, J.; Tundidor-Camba, A. Linear and nonlinear QSAR study of N-hydroxy-2-[(phenylsulfonyl)amino] acetamide derivatives as matrix metalloproteinase inhibitors. Bioorg. Med. Chem., 2006, 14, 4137-4150.
65. Becker, D.P.; DeCrescenzo, G.; Freskos, J.; Getman, D.P.; Hockerman, S.L.; Li, M.; Mehta, P.; Munie, G.E.; Swearingen, C. alphaAlkyl-alpha-amino-beta-sulphone hydroxamates as potent MMP inhibitors that spare MMP-1. Bioorg. Med. Chem. Lett., 2001, 11, 2723-2725.
66. Björklund, M.; Koivunen, E. Gelatinase-mediated migration and invasion of cancer cells. Biochim. Biophys. Acta, 2005, 1755, 37-69.
67. Tu, G.; Xu, W.; Huang, H.; Li, S. Progress in the development of matrix metalloproteinase inhibitors. Curr. Med. Chem., 2008, 15, 1388-1395.
68. Feng, X.; Danqing, S.; Yongsu, Z. In discussion of the inhibition of angiogenesis and its mechanism in Progress of Anti-neoplasmdrugs and Chemotherapy. Science Publishing Company. Beijing, 2001; Vol. 10, p. 243.
69. Li, Y.L.; Xu, W.F. Design, synthesis, and activity of caffeoyl pyrrolidine derivatives as potential gelatinase inhibitors. Bioorg. Med. Chem., 2004, 12, 5171-5180.
70. Kuo, H.C.; Kuo, W.H.; Lee, Y.J.; Lin, W.L.; Chou, F.P.; Tseng, T.H. Inhibitory effect of caffeic acid phenethyl ester on the growth of C6 glioma cells in vitro and in vivo. Cancer Lett., 2006, 234, 199-208.
71. Jiang, R.W.; Lau, K.M.; Hon, P.M.; Mak, T.C.; Woo, K.S.; Fung, K.P. Chemistry and biological activities of caffeic acid derivatives from Salvia miltiorrhiza. Curr. Med. Chem., 2005, 12, 237-246.
72. Qu, X.; Yuan, Y.; Xu, W.; Chen, M.; Cui, S.; Meng, H.; Li, Y.; Makuuchi, M.; Nakata, M.; Tang, W. Caffeoyl pyrrolidine derivative LY52 inhibits tumor invasion and metastasis via suppression of matrix metalloproteinase activity. Anticancer Res., 2006, 26, 3573-3578.
73. Qu, X.J.; Yuan, Y.X.; Tian, Z.G.; Xu, W.F.; Chen, M.H.; Cui, S.X.; Guo, Q.; Gai, R.; Makuuchi, M.; Nakata, M.; Tang, W. Using caffeoyl pyrrolidine derivative LY52, a potential inhibitor of matrix metalloproteinase-2, to suppress tumor invasion and metastasis. Int. J. Mol. Med., 2006, 18, 609-614.
74. Yuan, Y.X.; Xu, W.F.; Liu, J.; Chen, M.H.; Meng, H.; Qu, X.J. Inhibitory effects of matrix metalloproteinase (MMP) inhibitor LY52 on expression of MMP-2 and MMP-9 and invasive ability of human ovarian carcinoma cell line SKOV3. Ai Zheng, 2006, 25, 663-670.
75. Li, X.; Li, Y.; Xu, W. Design, synthesis, and evaluation of novel galloyl pyrrolidine derivatives as potential anti-tumor agents. Bioorg. Med. Chem., 2006, 14, 1287-1293.
76. Zhang, L.; Zhang, J.; Fang, H.; Wang, Q.; Xu, W. Design, synthesis and preliminary evaluation of new cinnamoyl pyrrolidine derivatives as potent gelatinase inhibitors. Bioorg. Med. Chem., 2006, 14, 8286-8294.
77. Cheng, X.C.; Wang, Q.; Fang, H.; Tang, W.; Xu, W.F. Synthesis of new sulfonyl pyrrolidine derivatives as matrix metalloproteinase inhibitors. Bioorg. Med. Chem., 2008, 16, 7932-7938.
78. Cheng, X.C.; Wang, Q.; Fang, H.; Tang, W.; Xu, W.F. Design, synthesis and evaluation of novel sulfonyl pyrrolidine derivatives as matrix metalloproteinase inhibitors. Bioorg. Med. Chem., 2008, 16, 5398-5404.
79. Cheng, X.C.; Wang, Q.; Fang, H.; Tang, W.; Xu, W.F. Design, synthesis and preliminary evaluation of novel pyrrolidine derivatives as matrix metalloproteinase inhibitors. Eur. J. Med. Chem., 2008, 43, 2130-2139.
80. Cheng, X.C.; Wang, Q.; Fang, H.; Xu, W.F. Role of sulfonamide group in matrix metalloproteinase inhibitors. Curr. Med. Chem., 2008, 15, 368-373.
81. Umezawa, H.; Aoyagi, T.; Tanaka, T.; Suda, H.; Okuyama, A.; Naganawa, H.; Hamada, M.; Takeuchi, T. Production of actinonin, an inhibitor of aminopeptidase M, by actinomycetes. J. Antibiot. (Tokyo), 1985, 38, 1629-1630.
82. Bertini, I.; Fragai, M.; Giachetti, A.; Luchinat, C.; Maletta, M.; Parigi, G.; Yeo, K.J. Combining in Silico tools and NMR data to validate protein-ligand structural models: application to matrix metalloproteinases. J. Med. Chem., 2005, 48, 7544-7559.
83. Aoyagi, T.; Yoshida, S.; Nakamura, Y.; Shigihara, Y.; Hamada, M.; Takeuchi, T. Probestin, a new inhibitor of aminopeptidase N, produced by Streptomyces azureus MH663-2F6. I. Taxonomy, production, isolation, physico-chemical properties, and biological activities. J. Antibiot. (Tokyo), 1990, 43, 143-148.
84. Chung, M.C.; Chun, H.K.; Han, K.H.; Lee, H.J.; Lee, C.H.; Kho, Y.H. MR-387A and B, new aminopeptidase N inhibitors, produced by Streptomyces neyagawaensis SL-387. J. Antibiot. (Tokyo), 1996, 49, 99-102.
85. Hidalgo, M.; Eckhardt, S.G. Matrix metalloproteinase inhibitors: how can we optimize their development? Ann. Oncol., 2001, 12, 285-287.
86. Ansorge, S.; Bank, U.; Heimburg, A.; Helmuth, M.; Koch, G.; Tadje, J.; Lendeckel, U.; Wolke, C.; Neubert, K.; Faust, J.; Fuchs, P.; Reinhold, D.; Thielitz, A.; Täger, M. Recent insights into the role of dipeptidyl aminopeptidase IV (DPIV) and aminopeptidase N (APN) families in immune functions. Clin. Chem. Lab Med., 2009, 47, 253-261.
87. Zhang, X.; Xu, W. Aminopeptidase N (APN/CD13) as a target for anti-cancer agent design. Curr. Med. Chem., 2008, 15, 2850-2865.